ABSTRACT
Lorvotuzumab mertansine (LM) is an ADC composed of an anti CD56 humanized N901 monoclonal antibody conjugated via a stable disulfide linker to the maytansinoid DM1. CD56 is expressed in up to 78% of multiple myelomas. LM displays antitumor activity in preclinical models of multiple myeloma. In a phase I study of MM, the MTD of single-agent LM was 112 mg/m 2 . The dose-limiting toxicities were grade 3 fatigue and grade 3 acute, reversible, renal failure. 2 PRs and 4 MRs were observed at various dose levels starting at 60 mg/m 2 . Building on the single agent experience, a phase II study of LM in combination with lenalidomide and dexamethasone was conducted. The optimal dose of LM was 75 mg/m 2 in the combination. The ORR was 56.4%. The most common treatment-related AE was peripheral neuropathy (PN), mostly grade 2 or less, with the majority of patients having a grade 1 PN at baseline. Continued evaluation of optimal dosing levels and schedules will be important to better define the utility of this promising treatment.
INTRODUCTION
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States with an estimated incidence of 21,700 and an estimated 10,710 deaths in 2012. (1) It is characterized by the proliferation and accumulation of clonal abnormal plasma cells. Treatment options have historically consisted of alkylating agents and steroids. The introduction of high dose chemotherapy, proteasome inhibitors (PIs) and immunomodulating drugs (IMiDs) have significantly expanded the treatment options and translated to deeper remissions and ultimately improved survival.(2) Despite these advances, MM remains an incurable disease with a median survival of 9 months once PIs and IMiDs have failed.(3) Novel therapeutic strategies are sorely needed. One such approach is the use of antibody-based therapy.
The success of monoclonal antibodies such as rituximab and trastuzumab for lymphoma and breast cancer, respectively, has greatly contributed to the ongoing quest for similar success in the treatment of MM. Until recently, the lack of specific and reproducible targets towards malignant plasma cells stalled progress in this disease. Currently, there are several targets that have been identified with directed antibodies to CD38,(4, 5) CS-1,(6, 7) FGFR3,(8) BAFF (9, 10) in clinical development. These monoclonal naked antibodies usually are functional and are dependent on mechanisms of action such as complement activation and/or ADCC to exert their anti-tumor effects. (5, 6) Monoclonal antibodies can also be exploited to serve as vehicles for on-target delivery of powerful therapy. Antibodies have been conjugated to radioactive isotopes and cytotoxic agents with various levels of success in different tumor types. without effects on CD56-negative MM cell lines. (26) Interestingly, the level of growth inhibition was independent of the level of expression of CD56 on the surface of the cells. Furthermore, the unconjugated lorvotuzumab antibody did not demonstrate any inhibitory effects whereas DM1 was inhibitory to both CD56-positive and CD56-negative cell lines. This nicely demonstrates the ability of the ADC to specifically deliver the cytotoxic agent to the cells expressing CD56 and sparing the cells that lack that expression. (26) Using a human CD56-positive MM xenograft model in severe combined immunodeficient (SCID) mice, LM was tested in both a minimal disease state and a bulky disease state. Mice were treated with LM, a saline placebo, unconjugated lorvotuzumab antibody or a control ADC that did not target CD56. Neither lorvotuzumab nor the control ADC showed any growth inhibition or survival benefit over placebo. Conversely, LM treatment led to a significant reduction in serum paraprotein, inhibition of tumor growth and an improved overall survival in the minimal disease state. Likewise, in the mice with bulky tumors, LM resulted in significant delayed tumor growth to complete inhibition of tumor growth with increasing doses and an improved overall survival at all doses tested. (26) 
In vitro and in vivo combination data in multiple myeloma
Using cultured human CD56-positive MM cell lines LM has been shown to have additive cytotoxic effects when combined with thalidomide and dexamethasone, and to have additive to synergistic effects when combined with melphalan. (30) Interestingly, combinations with bortezomib were found to be slightly antagonistic in vitro, but additive to synergistic in vivo. (30, 31) In combination with lenalidomide and lenalidomide plus dexamethasone, highly synergistic cytotoxic effects were seen. (31) Using MM xenografts in SCID mice, the additive and synergistic effects were able to be confirmed in vivo. Although LM treatment resulted in tumor regression at all doses tested, only one mouse had complete regression.(30) 
CLINICAL EVALUATION IN MULTIPLE MYELOMA

Clinical evaluation of LM single agent
Given the promising preclinical data, LM was initially evaluated as monotherapy in a phase I study in patients with relapsed and relapsed/refractory CD56-positive MM. The primary objective of the study was to determine the maximum tolerated dose (MTD), to determine pharmacokinetics (PK) and to assess preliminary signal of single agent activity.(33) LM was given intravenously (IV) at doses ranging from 40 to 140 mg/m 2 /week for two consecutive weeks with cycles repeating every three weeks. During the dose escalation phase of the study, patients were enrolled into each dose level in cohorts of three, with a dose-limiting toxicity (DLT) triggering cohort expansion. Once the MTD was determined, an expansion cohort at that dose level was opened to further characterize the safety and efficacy of LM. As of the most recent presentation, 37 patients had been treated on study.(34) The patients were very heavily pretreated with a median number of 6 prior MM therapies. Two patients experienced DLTs of grade 3 fatigue and grade 3 acute, reversible, renal failure at a dose of 140 mg/m 2 , and the MTD was declared at 112 mg/m 2 . A total of 19 patients were treated at the MTD.
The most common adverse events (AE) were fatigue, peripheral neuropathy (PN) and headache, while the most common abnormal laboratory findings included increased aspartate aminotransferase and increased uric acid. Six patients experienced drug-related grade 3 AEs: fatigue and renal failure (one patient) and one patient each with weakness, absence of deep tendon reflexes, myalgia, peripheral sensory neuropathy and elevated lipase. Only the renal failure met severe adverse event (SAE) criteria. There were no grade 4 drug-related AEs were reported. There was no evidence of infusion-related toxicity, hypersensitivity reactions or development of humoral response to either the lorvotuzumab antibody component 
Clinical evaluation of LM in combination
Building on the single agent experience and the promising in vitro and in vivo combination studies, a phase I study of LM in combination with lenalidomide and dexamethasone was initiated. In the dose escalation phase of the study patients with CD56-positive relapsed or relapsed/refractory MM with at least one prior treatment and no upper limit on number of prior treatments were included. Patients who had previously been treated or were refractory to lenalidomide were eligible for the doseescalation portion of the study. Patients who enrolled in the dose expansion cohort may have received lenalidomide previously, but must have achieved stable disease or better in response to prior lenalidomide therapy, and must have been > 6 months from their last full dose of lenalidomide. Table 1 . Although cycle 1 DLTs were not observed during the portion of this phase I study, grade 3 PN was observed in subsequent cycles of treatment and required dose reductions at dose levels of 90 mg/m 2 and 112 mg/m 2 . Based on this clinical observation and because clinical activity was seen at all dose levels, a dose of 75 mg/m 2 was ascertained to be the optimal dose for additional exploration in the expansion cohort. (36) A total of 44 patients (34 at the recommended expansion dose of 75 mg/m 2 ) were treated on study. The median number of prior treatments was 2 with 45% patients having had ≥ 3 prior treatments (91% had prior bortezomib, 75% had prior IMiDs, 59% had prior lenalidomide, 36% were refractory to their last treatment). Of the 44 patients enrolled, 39 were evaluable for response. Using the International Myeloma Working Group Criteria (IMWG), (37, 38) the overall response (OR) (defined as ≥PR) was 56.4% with a clinical response (defined as ≥MR) of 64.1% (1 stringent complete response (sCR), 11 very good partial remissions (VGPR), 10 PRs, 3 MR, 12 SD). In the lenalidomide naïve group, lenalidomide exposed/refractory, Abbreviations: PR, partial response; MR, minimal response. 1 Date of data cut-off: 16 November 2012 (represents both monitored and unmonitored data; data review ongoing), 2 Response evaluable patients received at least one dose of drug and 1 post-dose tumor assessment, 3 Relapsed and refractory myeloma: disease that is nonresponsive while on salvage therapy, or progresses within 60 days of last therapy in patients who have achieved > minimal response previously . Reproduced with permission from, (39). 
.
elapsed and refractory to last regimen, the OR was 87.5%, 34.8% and 50%, respectively. (See Table 2 ) The time to progression (TTP) of the 75 mg/m 2 expansion cohort was 7.7 months. (39) The most common AEs seen in ≥15% of patients that could be attributed to any of the study drugs are listed on Table 3 . The most common treatment-related AEs, listed in descending order, were PN, fatigue, neutropenia, thrombocytopenia, nausea and diarrhea. Most reports of PN were grade 2 or less with the majority of patients having a grade 1 PN at baseline. Nonetheless, PN was the single most common cause for dose reductions.
TOXICITY DISCUSSION
The expression of CD56 on normal human peripheral nerves, cardiac muscle, various neuroendocrine cells and NK cells may help explain some of the toxicities observed in the clinical trials. In preclinical studies in Cynomolgus monkeys, who share similar CD56 expression with humans, PN was seen at the highest doses tested. (ImmunoGen, Waltham, MA) Clinically, the most salient toxicity has been peripheral neuropathy both in the single agent and in combination with lenalidomide and dexamethasone. Given the preclinical toxicity data perhaps this should not be unexpected. Having said that, the PN seen in the MM studies seems more pronounced than that seen in solid tumors. (40) Most relapsed MM patients have baseline PN as a result of prior treatments or the disease itself, thus PN in this population may be more difficult to assess. Furthermore, other non CD56-directed ADCs using similar tubulin-disrupting cytotoxins have reported the emergence of PN as an important side effect. (19, 20) This would argue that perhaps the PN is more of a class effect in ADCs that utilize tubulin-acting cytotoxins due to low systemic levels of cytotoxin (or cytotoxin metabolites) released as a result of cellular catabolism following targetmediated or non target-mediated uptake mechanisms. (41) Further investigation as to the frequency of dosing and in less heavily pretreated MM populations would help define this particular toxicity.
CLINICAL PHARMACOLOGY
PK analyses in the single agent phase I study revealed an approximate linear relationship between dosing and observed maximal serum concentration.
The elimination half-life of the ADC ranged between 16-24 hours. Interestingly, the half-life of the lorvotuzumab antibody component and the intact ADC are similar suggesting that clearance of this particular ADC is driven by antigen-dependent process such as uptake by CD56-positive NK cells or CD56-positive tumor cells. Targeting of the ADC to myeloma cells was confirmed by immunohistochemical analysis of bone marrow tissue obtained one day post treatment. (33, 42) The PK parameters of LM for patients treated in combination with lenalidomide and dexamethasone in the expansion cohort (LM 75 mg/m 2 ) were generally similar to those observed with the single agent at this same dose. (39) Furthermore, the PK parameters of lenalidomide and dexamethasone in combination with LM at 75 mg/m 2 were similar to published reports of lenalidomide and dexamethasone.(43-45) These results suggest no drug-drug interaction with this combination.
CONCLUSION
Until recently, clinically effective antibody-based therapy has eluded MM. The lack of bulky tumor masses in the majority of patients with MM should theoretically allow for greater target exposure thus making MM an ideal cancer indication for antibody-based approaches. LM is the first ADC shown to have clinical activity in CD56-positive relapsed/refractory MM. The initial studies with single agent LM and in combination with lenalidomide and dexamethasone have reported significant objective responses and clinically relevant stable disease in heavily pretreated populations. In vitro studies clearly show that CD56 expression is imperative for on target delivery of the cytotoxic drug, though the level of expression required is not clear. (26) Why some patients respond while others do not remains an active area of investigation.
One can postulate that some mechanisms of resistance to ADCs may involve down regulation of the target, increased drug efflux, and downstream anti-apoptotic effects, among others. (46) To date, there is no clear evidence that LM leads to down regulation or loss of CD56 expression.
LM is generally very well tolerated. Similar to other ADCs containing tubulin-disrupting agents, PN has emerged as an important side effect. Continued evaluation of optimal dosing levels and schedules and treatment of patients earlier in the course of the disease prior to development of progressive neuropathy will be important to better help define the utility of this promising treatment. Finally, its favorable pharmacokinetics and minimal overlapping toxicities make LM ideal for continued exploration in combination studies.
